<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BACITRACIN</span><br/>(bass-i-tray'sin)<br/><span class="topboxtradename">Baciguent, </span><span class="topboxtradename">Bacitin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50,000 unit vial; 500 units/g cream</p>
<h1><a name="action">Actions</a></h1>
<p>Polypeptide antibiotic derived from cultures of <i>Bacillus subtilis</i>. Precise mechanism of action not known. Appears to interfere with function of bacterial cell membrane by inhibiting cell
         wall synthesis. Spectrum of antibacterial activity similar to that of penicillin. Bactericidal or bacteriostatic depending
         on concentration and susceptibility of organism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against many gram-positive organisms including <i>Streptococci, Staphylococci, Pneumococci, Corynebacteria, Clostridia, Neisseria, Haemophilus influenzae,</i> and <i>Treponema pallidum</i>. Also active against <i>Gonococci</i> and <i>Meningococci;</i> ineffective against most other gram-negative organisms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Parenteral therapy restricted to infants with <i>Staphylococcal</i> pneumonia and empyema due to susceptible organisms where adequate laboratory facilities and constant supervision are available.
         Used topically in treatment of superficial infections of skin.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Orally for treatment of antibiotic-associated colitis. Has been used investigationally by various routes (intrathecal, intrapleural,
         intrasynovial) for serious infections.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Toxic reaction or renal dysfunction associated with bacitracin; impaired renal function; atopic individuals; pregnancy (category
         C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myasthenia gravis or other neuromuscular disease. Patients allergic to neomycin may be sensitive to bacitracin.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Systemic Infections</span><br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 2.5 kg up to 1000 U/kg/24h divided q812h<br/><br/><span class="indicationtitle">Skin Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer of ointment b.i.d., t.i.d., as solution of 2501000 U/mL in wet dressing<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Do not use parenteral bacitracin for longer than 12 d.</li>
<li>Reconstitute with NS containing 2% procaine hydrochloride (prescribed). Do not reconstitute with diluents containing parabens
            because solution may precipitate or become cloudy.
         </li>
<li>Alternate injection sites since injections are painful.</li>
<li>Dry bacitracin vials should be stored in refrigerator at 2°8° C (36°46° F). Store solution
            for a maximum of 1 wk if refrigerated. Inactivation occurs at room temperature.
         </li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Clean affected area prior to application. May be covered with a sterile bandage.</li>
<li>Store ointments in tightly closed containers at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Anorexia, nausea, vomiting, diarrhea, rectal itching and burning. <span class="typehead">Hematologic:</span> Systemic use: Bone marrow depression, blood dyscrasias; eosinophilia. <span class="typehead">Body as a Whole:</span> Hypersensitivity (erythema, <span class="speceff-life">anaphylaxis</span>). <span class="typehead">Urogenital:</span>
<span class="speceff-life">Nephrotoxicity</span>, dose related: Increased BUN, uremia, <span class="speceff-life">renal tubular</span> and <span class="speceff-life">glomerular necrosis</span>. <span class="typehead">Special Senses:</span> Tinnitus.  <span class="typehead">Other:</span> Pain and inflammation at injection site, fever, superinfection, neuromuscular blockade <span class="speceff-life">with respiratory depression</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>  With <span class="classification">aminoglycosides</span>, possibility of additive nephrotoxic and neuromuscular blocking effects; with <b>tubocurarine</b> and other <span class="classification">nondepolarizing skeletal muscle relaxants</span>, possibility of additive neuromuscular blocking effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from intact or denuded skin or mucous membranes. <span class="typehead">Peak:</span> 12 h IM. <span class="typehead">Duration:</span> 68 h. <span class="typehead">Distribution:</span> Widely distributed including peritoneal and ascitic fluids. <span class="typehead">Elimination:</span> Slow renal excretion (1040% in 24 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline C&amp;S tests prior to initiation of therapy; start drug pending results.</li>
<li>Determine BUN and nonprotein nitrogen (NPN); examine urine for albumin, casts, and cellular elements, before systemic therapy
            is started. Monitor renal function daily throughout therapy.
         </li>
<li>Watch for signs of local allergic reaction (itching, burning, redness) with topical skin applications. Local reactions have
            preceded life-threatening anaphylactic episodes.
         </li>
<li>Monitor I&amp;O during parenteral therapy. Adequate urinary output is important to reduce possibility of renal toxicity. If fluid
            intake is inadequate or urinary output decreases, report to physician.
         </li>
<li>Inspect urine for turbidity and hematuria, and watch for other S&amp;S of urinary tract dysfunction. Report any changes in urination
            pattern (e.g., oliguria, urinary frequency, nocturia).
         </li>
<li>
            							Note: Prolonged use may result in overgrowth of nonsusceptible organisms, especially <i>Candida albicans</i>.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report local allergic reactions with topical applications (e.g., itching, burning, redness).</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>